資源描述：
《局部晚期非小細(xì)胞肺癌同步放化療前誘導(dǎo)化療的臨床研究.pdf》由會(huì)員上傳分享，免費(fèi)在線閱讀，更多相關(guān)內(nèi)容在行業(yè)資料-天天文庫。
1、現(xiàn)代腫瘤醫(yī)學(xué)2014年l2月第22卷第12期MODERNONCOLOGY，Dec．2014，VOL22，NO．12·2863·NarodSA．Bilateralbreastcancels[J]．NatRevClinOncol，2014，3：2590．11(3)：157—166．[14]WangT，IJiuH，ChenKX，eta1．Theriskfactorsandprognosisof[12]ShiYX，XiaQ，PengRJ，eta1．Comparisonofclinicopatholagicalbilateralprimarybreastcancer：Acomparati
2、vestudywithunilater-characteristicsandprognosesbetweenbilateralandunilateralalbreastcancer[J]．OncolRes，2011，19(34)：171—178．breastcancer[J]．JCancerResClinOncol，2012，138(4)：705—[15]ChenJJ，WangY，XueJY，eta1．Aclinic0path0localstudyof714．early—stagesynchronousbilateralbreastcancer：Aretrospective[1
3、3]ChenSF，DuCW，YangP，eta1．Themolecularandclinicopatho—evaluationandprospectivevalidationofpotentialriskfactors[J]．logiccharacteristicsofbilateralbreastcancer[J]．SciRep，2013，PLoSOne，2014，9(4)：e95185．(編校：張西敏)局部晚期非小細(xì)胞肺癌同步放化療前誘導(dǎo)化療的臨床研究吳偉，謝傳華，李金偉，張群貴，康昭洵Clinicalresearchofinductionchemotherapybefor
4、econcurrentchemoradiotherapyinIo—caladvancednon——small——celllungcancerWuWei，XieChuanhua，LiJinwei，ZhangQungui，KangZhaoxunDepartmentofRadiotherapy，TumorHospitalofGanzhou，JiangxiGanzhou341000，China．【Abstract】0bjective：Toexplorethepatternofchemotherapycombinedwithconcurrentchemoradiotherapy(CRT)
5、forlocalyadvancednon—smallcelllungcancer(LANSCLC)．Methods：Ninety—fourpatientswithLAN—SCLCbetweenMay2011andMay2013werereviewedandanalysed．A1lpatientsmeteligibilitycriteriaandweredi—videdintoA，B，Cgroups．GroupAreceivedconcurrent(CRT)atthestart，andthen4—6cyclesofadjuvantchemo—therapy．GroupBunder
6、went2cyclesofinductionchemotherapybeforeCRT，and2—4cyclesofadjuvantchemothera—PYafterCRT．GroupCexperienced4cyclesofinductionchemotherapybeforeCRTand0—2cyclesofadjuvantchem。otherapyafterCRT．Results：Therateoffollow—upwas95．7％．Objectiveresponses(ORR=CR+PR)inA，B，Cgroupswere67．7％，83．3％，66．7％，respe
7、ctively．Therewasnosignificantdiference(P=0．56)aboutORR．The1一yearand2一yearsurvivalofA，B，Cgroupswere70．3％，71．4％，78．5％and37．6％，36．9％，38．8％，respec—tively．Themediansurvivaltime(MST)was18．9months，17．9monthsand20．5months(P=0．763)forA，B，Cgroups，respectivel
